VKH
PVCT

Virtu KCG Holdings’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Virtu KCG Holdings’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-364,520
Closed -$36K – 4140
2016
Q3 		$36K Buy
364,520
+347,255
+2,011% +$75.7K ﹤0.01% 2837
2016
Q2 		$6K Sell
17,265
-8,419
-33% -$3.2K ﹤0.01% 2879
2016
Q1 		$10K Sell
25,684
-64,415
-71% -$26.5K ﹤0.01% 2659
2015
Q4 		$35K Sell
90,099
-2,487
-3% -$1.18K ﹤0.01% 3223
2015
Q3 		$53K Buy
92,586
+48,932
+112% +$25.1K ﹤0.01% 2989
2015
Q2 		$24K Sell
43,654
-79,101
-64% -$64.5K ﹤0.01% 3175
2015
Q1 		$100K Sell
122,755
-374,361
-75% -$309K ﹤0.01% 2653
2014
Q4 		$398K Buy
497,116
+483,558
+3,567% +$442K 0.01% 1978
2014
Q3 		$14K Sell
13,558
-74,468
-85% -$72.2K ﹤0.01% 3497
2014
Q2 		$76K Buy
+88,026
New +$105K ﹤0.01% 3350

Other funds holding PVCT

CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Virtu KCG Holdings's PVCT Position: Q4 2016 in Review

Virtu KCG Holdings sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 364,520 shares — an estimated $36K sold.

Virtu KCG Holdings first reported a position in PVCT in Q2 2014 and held it in 10 quarters. The position peaked at $398K in Q4 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

  • Virtu KCG Holdings reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 364,520 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $36K.
  • Virtu KCG Holdings first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 10 quarters.
  • Virtu KCG Holdings's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $398K in Q4 2014.
  • 8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.